RVMD News and Press, Revolution Medicines Inc. From 02/27/23

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RAS MULTI ) and RMC-6291 (KRAS G12C ) expected in 2023 RMC-9805 (KRAS G1 2D ) expected to begin clinica...

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Mon...

REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairm...

Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric mTORC1-Selective Inhibitor and a KRAS G12C -Selective Inhibitor in P...

Sanofi ( NASDAQ: SNY ) has terminated a development and collaboration agreement with Revolution Medicines ( NASDAQ: RVMD ) for SHP inhibitor drugs. As a result, Revolution Medicines ( RVMD ) will regain rights to RMC-4630, a SHP2 inhibitor drug candidate for RAS-addicted...

Summary Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy. The company is well-capitalized to continue operations and clinical advancements. The market is recognizing Revolution Medici...

REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Sanofi has provided notice of termination of the parties’ global SHP2 developmen...

Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Conference Call November 7, 2022 16:30 ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance & ...

Revolution Medicines press release ( NASDAQ: RVMD ): Q3 GAAP EPS of -$0.87 misses by $0.02 . Revenue of $3.4M (+209.1% Y/Y) misses by $2.94M . Cash, cash equivalents and marketable securities were $655.0 million as of September 30, 2022, compared to $577.1 mill...

Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RAS MULTI inhibitor) and RMC-6291 (KRAS G12C inhibitor) Completed successful equity financing to support advancement of pipeline Webcast t...